Experience

Intellectual Property Office of New Zealand (IPONZ)

• New Zealand
• Government Administration
• 1 - 100 Employee

• Senior Patent Examiner

  • Nov 2022 - Present

• Patent Examiner

  • Jan 2018 - Nov 2022



Malaghan Institute of Medical Research

• New Zealand
• Research Services
• 1 - 100 Employee

• Research Officer

  • Jan 2017 - Dec 2017

• Masters Student

  • Jan 2016 - Jan 2017



Sanquin

• Netherlands
• Hospitals and Health Care
• 700 & Above Employee

• Intern

  • Sep 2012 - Apr 2013

  Research involved IgG4 B cells. Mainly the part they play in the immune system and in particular how they compete with IgE B cells during an allergic reaction. Skills: B cell isolation from blood, cell culture (B cells, El4 cells in suspension and 3T3 cells adhered), FACS analysis and sort, fluorescent labelling of antibodies, ELISA. L. Lighaam et. al. (2014) Phenotypic differences between IgG4 and IgG1 B cells point to distinct regulation of the IgG4 response. JACI 133(1) : 267-270 Research involved IgG4 B cells. Mainly the part they play in the immune system and in particular how they compete with IgE B cells during an allergic reaction. Skills: B cell isolation from blood, cell culture (B cells, El4 cells in suspension and 3T3 cells adhered), FACS analysis and sort, fluorescent labelling of antibodies, ELISA. L. Lighaam et. al. (2014) Phenotypic differences between IgG4 and IgG1 B cells point to distinct regulation of the IgG4 response. JACI 133(1) : 267-270



Amsterdam UMC

• Netherlands
• Hospitals and Health Care
• 700 & Above Employee

• Intern

  • Feb 2012 - Aug 2012

  A retrospective study in which immunohistochemistry is being used to determine the expression of immune (escape) markers and if a biomarker can be used in future to predict the patient outcome of fase III and IV melanoma after treatment with immunotherapy. Skills: Immunohistochemistry (frozen and paraffin) E.P.M. Tjin et. al. (2014) Immune escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy. Cancer Immunology Research 2(6): 538-546 A retrospective study in which immunohistochemistry is being used to determine the expression of immune (escape) markers and if a biomarker can be used in future to predict the patient outcome of fase III and IV melanoma after treatment with immunotherapy. Skills: Immunohistochemistry (frozen and paraffin) E.P.M. Tjin et. al. (2014) Immune escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy. Cancer Immunology Research 2(6): 538-546